The FULL 2020 agenda has not yet been announced. Please check back in the coming weeks for updates or join our mailing list HERE. Below are featured presentations scheduled to date.
APRIL 21, 2020
Designing Living Diagnostics and Therapeutics for the Microbiome
We can engineer the microbiome to report on the health of the gut microbiome and report on the presence of pathological states such as inflammation. These sensor bacteria can also be engineered to deliver therapeutics on demand. We also use targeted bacteriophage to shape and program the gut microbiome. In doing so, we have developed novel targeted therapeutic strategies.
Pamela Silver, Ph.D., Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology, Harvard Medical School
Scalable Approaches for Bacteriophage Manufacture, Their Formulation and Encapsulation for Targeted Delivery and Controlled Release
Targeted delivery of therapeutic concentrations of bacteriophages and phage associated antibacterials such as endolysins whilst preventing phage inactivation due to environmental stresses during manufacture and delivery e.g. acidity of the stomach or enzymatic degradation in the gastrointestinal tract.
Danish Malik, Ph.D., Senior Lecturer, Chemical Engineering Department, Loughborough University
Use of Phage Cocktail in Chronic Disease Indications (non-CME presentation)
In this presentation, Mr. Oron will discuss the following:
♦ A clinical trial for evaluating BX001 for acne prone skin
♦ BX002 targeting a novel proinflammatory target in inflammatory bowel disease
Assaf Oron, Chief Business Officer, BiomX
Optimized Microbiome Workflow: Towards Microbiome-Based Diagnostics & Therapeutics Solutions (non-CME presentation)
The human gut microbiome has been described as the most complex ecosystem on earth. As microbiome research evolves, more and more health conditions are being linked to an unbalanced microbial composition. As microbiome research gradually moved from association to causation, the complexity increases as we move from genome to transcriptome, proteome, metabolome and beyond. Because the methods and tools to make measurements of the microbiome vary widely, results produced by different laboratories are often not comparable. Standards and validated protocols are crucial for gaining a full picture of the microbiome’s basic features, as well as translating it into therapeutic strategies.
Michal Daniely, Ph.D., Research and Development Director, Millipore Sigma
Advanced High-Quality Microbiome Analysis as The Key to Unlocking Commercial and Scientific Value from Clinical Studies (non-CME presentation)
Jack Egelund Madsen, Ph.D., Chief Business Officer, Clinical Microbiomics
APRIL 22, 2020
Science to Market: From a Bacterial Strain to a Skincare Product (non-CME presentation)
Lionel Breton, Ph.D., DSc, Scientific Director, L'Oreal Advanced Research, L'Oreal
Considerations for Gut-Based Brain Research
Much research in neuroscience has neglected the rest of the body, until recently, when the “gut-brain axis” has come to light. From the perspective of a neuroscientist, this talk will cover considerations in clinical trials and basic science research to incorporate questions about the gut to more holistically assess neurological disease. Lessons learned from our research on Alzheimer's disease will serve as a concrete reference.
Amy Feehan, Ph.D., Research Scientist, Ochsner Health System
Gut Microbiota Mediates the Vascular Beneficial Effects of Dietary Anthocyanins
Clinical studies support the cardiovascular benefits of berry anthocyanins. This presentation will focus on how dietary blueberry anthocyanins shift the composition and functional potential of the gut microbiome and improve vascular health in preclinical models. This presentation will also discuss the role of the gut microbiome and anthocyanin-derived microbial metabolites in mediating the vascular effects of blueberries.
Anandh Babu Pon Velayutham, Ph.D., Associate Professor, Nutrition & Integrative Physiology, University of Utah
The Continued Struggle to Fund Women's Healthcare (non-CME presentation)
Rachel Teitelbaum, Ph.D., Chief Executive Officer, Hervana
ACS Extramural Research: Portfolio, Programs and Funding Opportunities
Lynne Elmore, Ph.D., Director, Translational Cancer Research Program, American Cancer Society
Development, Validation, and Unique Applications of Species-specific Microbiome Assay & Database that together Provide True Pan-Domain Molecular Diagnostics
Garth Ehrlich, Ph.D., Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery, Drexel University College of Medicine
OPTIMISTICC: An Opportunity to Investigate the Microbiomes Impact in the Science and Treatment of Colorectal Cancer
Wendy Garrett, Ph.D., Prof. of Immunology & Infectious Diseases, Dept. of Genetics & Complex Diseases, Dept. of Medicine, Harvard Medical School
A Survivor’s Perspective: The Bigger Picture of the Patient Journey.
Too often, manufacturers of therapeutics forget that the patient is more than simply someone taking a pill, but a person on an often long and arduous journey; a journey in which a therapeutics manufacturer can and often should become more than simply a supplier, but a trusted partner. In this presentation, Nancy C. Caralla, Founder of the C Diff Foundation and three-time C. difficile infection survivor, will share first-hand knowledge of one patient's journey that will bring needed perspective to the audience and new insights that should be front of mind for anyone developing new microbiome therapies.
Nancy Caralla, Foundiing President, Executive Director, C Diff Foundation
Development of a Pill to Do In Vitro Microbiome Sampling and Differences Found
Sameer Sonkusale, Ph.D., Prof. of Electrical & Computer Engineering, Prof. of Biomedical Engineering (adjunct), Director/Principal Investigator, Nano Lab, Tufts University
Gut Microbiota Induces Anti-Tumor Immunity Restricting Tumor Growth – The RNF5-UPR-Inulin Journey
This presentation will highlight studies in which we have demonstrated the importance of the ubiquitin ligase RNF5 in the control of gut microbiota composition with a concomitant effect on anti-tumor immunity and tumor growth inhibition. The role of Unfolded Protein Response in RNF5-mediated changes in gut microbiota and ant-tumor immunity will be discussed, and finally, the identification of prebiotics that are capable of inducing anti-tumor immunity and restrict tumor growth.
Ze'ev Ronai, Ph.D., Professor, Sanford Burnham Prebys Medical Discovery Institute
APRIL 23, 2020
Data-Driven Personalized Nutrition to Modulate Gut Microbiome Functions: Towards Prevention of Chronic Diseases (non-CME presentation)
Gut microbiome dysbiosis has been studied in the context of taxonomy, but research in this area has yielded very little actionable information. Viome focuses on the microbial functional dysbiosis, which we have tied to several chronic diseases. Not only is the functional dysbiosis more predictive of chronic diseases, it is very actionable. Microbial functions are mostly determined by the molecules in the foods we consume. Therefore, microbial functions can be modulated by adjusting each person's diet to support healthy microbial functions, and shut down those associated with disease. Viome's systems biology platform and results from several large studies will be presented.
Momo Vuyisch, Ph.D., Chief Scientific Officer, Viome
Microbiome Funding Opportunities with the ISS
Rachel Clemens, Ph.D., Commercial Innovation Manager, Life Science Lead, ISS US National Lab, Center for Advancement in Science in Space
Fecal Microbiota Transplantation in Treating Autism
Dae-Wook Kang, Ph.D., Assistant Professor, Department of Civil & Environmental Engineering, University of Toledo
Reverse Translation in the Microbiome: Leveraging Clinical Data to Identify Microbes Driving Patient Outcomes (non-CME presentation)
Data from whole-community microbial transfers in patients can provide proof-of-concept to retire risk early in the development of novel microbial therapies. Leveraging data from thousands of patients, Finch has developed a Human First Discovery platform to rapidly translate clinical data into new products in diverse therapeutic areas ranging from ulcerative colitis to autism spectrum disorder.
Sonia Timberlake, Ph.D., Vice President of Research, Finch Therapeutics
The Use of Wild Mouse Models to Further Microbiome Research
Barbara Rehermann, MD, Section Chief, Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health
The Role of Fungi in Microbiome Science
Mahmoud Ghannoum, Ph.D., EMBA, Professor, Department of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center
Immunotherapeutic Approaches to Selective Modification of Microbiome Structure and Function (non-CME presentation)
This presentation will highlight the ways that conventional antibody science has advanced conventional organ/system research and then outline ways in which we can now intervene quite specifically in dysbiosis-driven pathogenesis. Several examples of emerging discrete pathways that are enlightening us will be presented on colorectal cancer pathogenesis and undesirable drug metabolism of levodopa, and use these as examples of direct application of our IgY (avian antibody) technology.
Julius Goepp, MD, Chief Executive Officer, Scaled Microbiomics
Lupus and Dysbiosis in the Gut Microbiome: Cause or Effect or Both?
Throughout our lives we are immersed in, and colonized by, immense and complex microbial communities. Yet, at times imbalances within microbiota contribute to metabolic and immune regulatory abnormalities that underlie the development of inflammatory and autoimmune diseases. Recent progress in investigations of the microbiome are beginning to illuminate aspects of the pathogenesis of Systemic Lupus Erythematosus, and may suggest that interconnections with specific disease-associated patterns of dysbiosis within gut communities could be bidirectional and mutually reinforcing.
Gregg Silverman, MD, Professor of Medicine & Pathology, New York University School of Medicine
A New Era in Microbiome Research: The Prospector Array Based Microbial Cultivation and Screening Platform (non-CME presentation)
Deep insights into microbiome structure and function are the foundation for microbial applications in human health, agriculture, environment, and industry. Antiquated, labor intensive methodologies currently used to cultivate microbes are a significant barrier to access microbes from microbiome samples for research and product development. The Prospector platform with its highly dense array of > 6000 nanoscale cultivation chambers integrated with an instrument that automates the cultivation workflow can enable researchers to isolate 1000s of microbes in parallel for microbiome analysis at an unprecedented scale.
Peter Christey, Ph.D., CEO and Co-Founder, General Automation Technology Labs (GALT)
Please Note the Above is a Partial Agenda. Please Check Back in the Coming Weeks for Additions to this Agenda